166 related articles for article (PubMed ID: 17133266)
1. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
Hong YS; Lee HR; Park S; Lee SC; Hwang IG; Park BB; Lee J; Ahn JS; Ahn MJ; Lim HY; Park K
Br J Cancer; 2006 Dec; 95(12):1648-52. PubMed ID: 17133266
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
[TBL] [Abstract][Full Text] [Related]
6. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
[TBL] [Abstract][Full Text] [Related]
10. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
Han JY; Lee DH; Lee SY; Park CG; Kim HY; Kim EA; Yoon SM; Lee HG; Lee JS
Med Oncol; 2005; 22(3):281-90. PubMed ID: 16110139
[TBL] [Abstract][Full Text] [Related]
14. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
15. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
[TBL] [Abstract][Full Text] [Related]
17. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Briasoulis E; Samantas E; Kalofonos H; Skarlos D; Makatsoris T; Christodoulou C; Fountzilas G; Bamias A; Dimopoulos MA; Kosmidis P; Pavlidis N
Cancer Chemother Pharmacol; 2005 Nov; 56(5):521-8. PubMed ID: 15959778
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
